Insiders Updates Analyzing Allogene Therapeutics Inc (ALLO) After Recent Trading Activity Allogene Therapeutics Inc’s recently made public that its Director MESSEMER DEBORAH M. unloaded Company’s shares for reported $52377.0 on Jun
Featured Allogene Therapeutics, Inc. (ALLO) Stock Dipping in Aftermarket, Here’s Why Allogene Therapeutics, Inc. (ALLO), a clinical-stage immuno-oncology company, has dipped 32.73% and hence, ALLO stock was trading at $16.40 when